<DOC>
	<DOCNO>NCT00455195</DOCNO>
	<brief_summary>Pompe disease ( also know glycogen storage disease Type II ) cause deficiency critical enzyme body call acid alpha-glucosidase ( GAA ) . Normally , GAA use body 's cell break glycogen ( stored form sugar ) within specialized structure call lysosome . In patient Pompe disease , excessive amount glycogen accumulates store various tissue , especially heart skeletal muscle , prevents normal function . The objective extension study ass long-term safety efficacy alglucosidase alfa treatment patient Late-Onset Pompe Disease previously treat placebo-controlled , double-blind study AGLU02704 ( NCT00158600 ) .</brief_summary>
	<brief_title>Late-Onset Treatment Study Extension Protocol</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Patient must complete protocol AGLU02704 ( NCT00158600 ) Patient must provide sign , inform consent prior perform studyrelated procedure Patient ( patient 's legal guardian patient 18 year age ) must ability comply clinical protocol A female patient childbearing potential must negative pregnancy test Baseline . ( note : female patient childbearing potential sexually mature male must use medically accept method contraception throughout study . ) The patient medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude treatment alglucosidase alfa .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>